CL2004000633A1 - Compuestos copolimeros, composicion farmaceutica que los contiene y procedimiento de preparacion, utiles en el tratamiento de enfermedades metabolicas oseas. - Google Patents
Compuestos copolimeros, composicion farmaceutica que los contiene y procedimiento de preparacion, utiles en el tratamiento de enfermedades metabolicas oseas.Info
- Publication number
- CL2004000633A1 CL2004000633A1 CL200400633A CL2004000633A CL2004000633A1 CL 2004000633 A1 CL2004000633 A1 CL 2004000633A1 CL 200400633 A CL200400633 A CL 200400633A CL 2004000633 A CL2004000633 A CL 2004000633A CL 2004000633 A1 CL2004000633 A1 CL 2004000633A1
- Authority
- CL
- Chile
- Prior art keywords
- oseas
- useful
- treatment
- pharmaceutical composition
- metabolic diseases
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F216/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by an alcohol, ether, aldehydo, ketonic, acetal or ketal radical
- C08F216/12—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by an alcohol, ether, aldehydo, ketonic, acetal or ketal radical by an ether radical
- C08F216/14—Monomers containing only one unsaturated aliphatic radical
- C08F216/16—Monomers containing no hetero atoms other than the ether oxygen
- C08F216/18—Acyclic compounds
- C08F216/20—Monomers containing three or more carbon atoms in the unsaturated aliphatic radical
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L71/00—Compositions of polyethers obtained by reactions forming an ether link in the main chain; Compositions of derivatives of such polymers
- C08L71/02—Polyalkylene oxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F222/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a carboxyl radical and containing at least one other carboxyl radical in the molecule; Salts, anhydrides, esters, amides, imides, or nitriles thereof
- C08F222/04—Anhydrides, e.g. cyclic anhydrides
- C08F222/06—Maleic anhydride
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F8/00—Chemical modification by after-treatment
- C08F8/30—Introducing nitrogen atoms or nitrogen-containing groups
- C08F8/32—Introducing nitrogen atoms or nitrogen-containing groups by reaction with amines
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F216/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by an alcohol, ether, aldehydo, ketonic, acetal or ketal radical
- C08F216/12—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by an alcohol, ether, aldehydo, ketonic, acetal or ketal radical by an ether radical
- C08F216/14—Monomers containing only one unsaturated aliphatic radical
- C08F216/1416—Monomers containing oxygen in addition to the ether oxygen, e.g. allyl glycidyl ether
- C08F216/1425—Monomers containing side chains of polyether groups
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L2203/00—Applications
- C08L2203/02—Applications for biomedical use
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Polymers & Plastics (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2003080389 | 2003-03-24 | ||
| JP2003355853 | 2003-10-16 | ||
| JP2003426598 | 2003-12-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2004000633A1 true CL2004000633A1 (es) | 2005-01-21 |
Family
ID=33101948
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL200400633A CL2004000633A1 (es) | 2003-03-24 | 2004-03-24 | Compuestos copolimeros, composicion farmaceutica que los contiene y procedimiento de preparacion, utiles en el tratamiento de enfermedades metabolicas oseas. |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US7811556B2 (es) |
| EP (1) | EP1611173B1 (es) |
| KR (1) | KR20050118201A (es) |
| AR (1) | AR043917A1 (es) |
| AT (1) | ATE388173T1 (es) |
| AU (1) | AU2004223964B2 (es) |
| BR (1) | BRPI0408526A (es) |
| CA (1) | CA2520450C (es) |
| CL (1) | CL2004000633A1 (es) |
| DE (1) | DE602004012241T2 (es) |
| DK (1) | DK1611173T3 (es) |
| ES (1) | ES2301978T3 (es) |
| IL (1) | IL170489A (es) |
| MX (1) | MXPA05010289A (es) |
| NZ (1) | NZ542352A (es) |
| PA (1) | PA8598701A1 (es) |
| PE (1) | PE20041067A1 (es) |
| PL (1) | PL1611173T3 (es) |
| PT (1) | PT1611173E (es) |
| SI (1) | SI1611173T1 (es) |
| TW (1) | TWI293882B (es) |
| WO (1) | WO2004085500A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2090599A1 (de) * | 2008-02-13 | 2009-08-19 | Construction Research and Technology GmbH | Copolymer mit Polyetherseitenketten und Dicarbonsäurederivatbausteinen |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1217005A (en) | 1916-05-08 | 1917-02-20 | Judson D Mccarthy | Photographic-printing frame. |
| US4471100A (en) * | 1981-01-16 | 1984-09-11 | Nippon Shokubai Kagaku Kogyo Co., Ltd. | Copolymer and method for manufacture thereof |
| JP2621308B2 (ja) | 1987-03-13 | 1997-06-18 | 日本油脂株式会社 | アリルエーテル−無水マレイン酸共重合体 |
| JP2701295B2 (ja) | 1987-03-13 | 1998-01-21 | 日本油脂株式会社 | アリルエーテル−無水マレイン酸共重合体 |
| JP2803265B2 (ja) | 1989-12-26 | 1998-09-24 | 日本油脂株式会社 | 変性ポリペプチドおよびその用途 |
| US5158622A (en) * | 1991-02-12 | 1992-10-27 | Betz Laboratories, Inc. | Method and composition for treatment of aluminum |
| JP3271265B2 (ja) * | 1991-03-07 | 2002-04-02 | 日本油脂株式会社 | 修飾プロテアーゼ |
| JP3035675B2 (ja) * | 1991-08-21 | 2000-04-24 | 株式会社コーセー | 修飾スーパーオキシドディスムターゼ |
| CA2080174A1 (en) | 1991-10-11 | 1993-04-12 | John E. Hayes | Polymer polyol dispersants from polymers containing anhydride groups |
| JP3106265B2 (ja) | 1992-05-26 | 2000-11-06 | 株式会社コーセー | 修飾リゾチーム |
| US6004583A (en) | 1995-03-22 | 1999-12-21 | Orex Pharmaceutical Development Corp. | Protein-containing polymer composition for oral administration |
| US6369027B1 (en) | 1995-12-22 | 2002-04-09 | Amgen Inc. | Osteoprotegerin |
| IT1293087B1 (it) | 1997-07-10 | 1999-02-11 | Isi Ist Sierovaccinogeno Ital | Microparticelle a base di materiali polimerici ibridi per il rilascio controllato di molecole biologicamente attive, procedimento per la |
| DE19834173A1 (de) * | 1997-08-01 | 1999-02-04 | Sueddeutsche Kalkstickstoff | Copolymere auf Basis von ungesättigten Dicarbonsäure-Derivaten und Oxyalkylenglykol-Alkenylethern |
| JPH11302199A (ja) | 1998-04-16 | 1999-11-02 | Sankyo Co Ltd | 薬物運搬体を構成するグラフト共重合体 |
| DE19847868C2 (de) * | 1998-10-16 | 2003-09-25 | Clariant Gmbh | Sprengstoffe, enthaltend modifizierte Copolymere aus Polyisobutylen und Maleinsäureanhydrid als Emulgatoren |
| CA2358463A1 (en) * | 1999-01-08 | 2000-07-13 | Virginia Commonwealth University | Polymeric delivery agents and delivery agent compounds |
| ITTO20000942A1 (it) | 2000-10-10 | 2001-01-10 | Sergio Guzzoni | Pricedimento per la gestione di interscambi di messaggi tra fornitorie clienti di servizi di telefonia. |
| JP5109218B2 (ja) | 2001-09-28 | 2012-12-26 | 日油株式会社 | 共重合体の製造方法 |
| JP2003105040A (ja) | 2001-09-28 | 2003-04-09 | Nof Corp | 共重合体の製造方法およびその用途 |
-
2004
- 2004-03-23 TW TW093107766A patent/TWI293882B/zh not_active IP Right Cessation
- 2004-03-24 SI SI200430653T patent/SI1611173T1/sl unknown
- 2004-03-24 PL PL04723056T patent/PL1611173T3/pl unknown
- 2004-03-24 AR ARP040100985A patent/AR043917A1/es unknown
- 2004-03-24 ES ES04723056T patent/ES2301978T3/es not_active Expired - Lifetime
- 2004-03-24 PT PT04723056T patent/PT1611173E/pt unknown
- 2004-03-24 WO PCT/JP2004/004134 patent/WO2004085500A1/en not_active Ceased
- 2004-03-24 CL CL200400633A patent/CL2004000633A1/es unknown
- 2004-03-24 PA PA20048598701A patent/PA8598701A1/es unknown
- 2004-03-24 MX MXPA05010289A patent/MXPA05010289A/es active IP Right Grant
- 2004-03-24 AT AT04723056T patent/ATE388173T1/de not_active IP Right Cessation
- 2004-03-24 DK DK04723056T patent/DK1611173T3/da active
- 2004-03-24 PE PE2004000304A patent/PE20041067A1/es not_active Application Discontinuation
- 2004-03-24 KR KR1020057017757A patent/KR20050118201A/ko not_active Ceased
- 2004-03-24 DE DE602004012241T patent/DE602004012241T2/de not_active Expired - Lifetime
- 2004-03-24 NZ NZ542352A patent/NZ542352A/en unknown
- 2004-03-24 AU AU2004223964A patent/AU2004223964B2/en not_active Ceased
- 2004-03-24 EP EP04723056A patent/EP1611173B1/en not_active Expired - Lifetime
- 2004-03-24 CA CA002520450A patent/CA2520450C/en not_active Expired - Fee Related
- 2004-03-24 BR BRPI0408526-4A patent/BRPI0408526A/pt not_active IP Right Cessation
-
2005
- 2005-08-25 IL IL170489A patent/IL170489A/en not_active IP Right Cessation
- 2005-09-22 US US11/231,963 patent/US7811556B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| KR20050118201A (ko) | 2005-12-15 |
| NZ542352A (en) | 2007-02-23 |
| AU2004223964B2 (en) | 2007-02-22 |
| CA2520450A1 (en) | 2004-10-07 |
| IL170489A (en) | 2009-06-15 |
| AU2004223964A1 (en) | 2004-10-07 |
| DE602004012241D1 (de) | 2008-04-17 |
| US20060062754A1 (en) | 2006-03-23 |
| DE602004012241T2 (de) | 2009-03-12 |
| EP1611173B1 (en) | 2008-03-05 |
| PA8598701A1 (es) | 2005-02-04 |
| ES2301978T3 (es) | 2008-07-01 |
| PL1611173T3 (pl) | 2008-08-29 |
| AR043917A1 (es) | 2005-08-17 |
| PT1611173E (pt) | 2008-05-23 |
| DK1611173T3 (da) | 2008-06-23 |
| BRPI0408526A (pt) | 2006-03-07 |
| SI1611173T1 (sl) | 2008-08-31 |
| EP1611173A1 (en) | 2006-01-04 |
| HK1078598A1 (en) | 2006-03-17 |
| ATE388173T1 (de) | 2008-03-15 |
| TWI293882B (en) | 2008-03-01 |
| WO2004085500A1 (en) | 2004-10-07 |
| US7811556B2 (en) | 2010-10-12 |
| PE20041067A1 (es) | 2005-01-22 |
| CA2520450C (en) | 2009-11-03 |
| MXPA05010289A (es) | 2005-11-17 |
| TW200501986A (en) | 2005-01-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR8642A (es) | Compuestos, composiciones farmaceuticas y metodos para su uso en el tratameinto de desordenes metabolicos | |
| EP1513825A4 (en) | ANTITU-CULINARY MEDICAMENT: COMPOSITIONS AND METHODS | |
| CL2003002287A1 (es) | COMPUESTOS DERIVADOS DE TIENO[3,2-b]-PIRIDINA-6-CARBONITRILOS Y TIENEO[2,3-b]-PIRIDINA-5-CARBONITRILOS, COMPOSICION FARMACEUTICA, PROCEDIMIENTO DE PREPARACION Y COMPUESTOS INTERMEDIARIOS, Y SU USO EN EL TRATAMIENTO DEL CANCER, APOPLEJIA, OSTEOPOROSIS | |
| BRPI0806531A2 (pt) | Composto, composição farmacêutica, agente terapêutico, e, uso do composto. | |
| WO2004006858A3 (en) | Compounds, compositions, and methods employing same | |
| CL2007002261A1 (es) | Compuestos derivados de imidazo[1,2-b]piridazina, inhibidores de quinasa; composicion farmaceutica; y uso en el tratamiento o prevencion del cancer. | |
| CL2004001069A1 (es) | Compuestos derivados de 1-benzoil-isoquinolinas sustituidos; procedimiento de preparacion, composicion farmaceutica; y uso para el tratamiento o profilaxis de diabetes tipo ii. | |
| RS20120139A3 (en) | 8-[3-amino-piperidin-1-yl]-xanthines, the production thereof and the use of the same as medicaments | |
| NO20053920D0 (no) | Preparat for og behandling av demyelineringssykdommer og paralyse ved administrering av remyelineringsmidler. | |
| HUS1500048I1 (hu) | Ivermectin helyi kiszerelése dermatológiai állapotok kezelésére | |
| IS8398A (is) | Lyfjasamsetningar til að meðhöndla æxli | |
| CL2007001918A1 (es) | Compuestos derivados heteroarilos sustituidos; metodo para la preparacion de los compuestos; composicion farmaceutica; y uso para el tratamiento del dolor, depresion, enfermedad de alzheimer e hipertension entre otras. | |
| CL2007002207A1 (es) | Compuestos derivados de sulfonilaminas; composicion farmaceutica; y uso de los compuestos en el tratamiento del glaucoma. | |
| CL2007000161A1 (es) | Compuestos derivados de 2,4-dioxoimidazolidina sustituida, inhibidores de proteinas cinasas; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer. | |
| ITMI20031570A1 (it) | Composizione per uso dietetico, farmaceutico o cosmetico | |
| ATE401875T1 (de) | Pharmazeutische feste dispersionen von modafinil- verbindungen | |
| DE502004002571D1 (de) | Substituierte 3-pyrrolidin-indol-derivate | |
| CL2007003038A1 (es) | Compuestos derivados de 2-fenil-6-aminocarbonil-pirimidina; composicion farmaceutica; y uso en el tratamiento de trastornos vasculares oclusivos. | |
| AR109263A2 (es) | Composición que comprende moxidectina | |
| CL2007002619A1 (es) | Compuestos derivados de 3-aza-biciclo[4.1.0]heptano; composicion farmaceutica; y uso en el tratamiento de la depresion. | |
| CL2008002082A1 (es) | Compuestos derivados de 6-fenil-1h-imidazo[4,5-c]piridina-4-carbonitrilo, inhibidores de catepsina s y catepsina k; composicion farmaceutica; y uso en el tratamiento de osteoporosis, aterosclerosis, inflamacion, entre otras enfermedades. | |
| CL2007003643A1 (es) | Composicion farmaceutica de azimilidina que comprende 0,5% a aproximadamente 2,5% (w/w) de agua; y uso para el tratamiento de arritmias cardiacas. | |
| DE60142913D1 (de) | Arzneilösungen enthaltend modafinilverbindungen | |
| NO20055136D0 (no) | Farmasoytisk sammensetning som innbeffatter et immunosuppressivt stoff for bruk ved behandling av hudsykdommer | |
| CL2007002769A1 (es) | Compuestos derivados de sulfonamida; procedimiento de obtencion; composicion farmaceutica; y uso en el tratamiento de la diabetes. |